Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Apexigen, Inc.	Pfizer License Agreement	Common Stock	Common Stock Apexigen, Inc.	Common Stock Pfizer License Agreement	Additional Paid-in Capital	Additional Paid-in Capital Apexigen, Inc.	Additional Paid-in Capital Pfizer License Agreement	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance at Dec. 31, 2022	$ 160,824			$ 34			$ 373,225				$ (212,435)
Beginning Balance, Shares at Dec. 31, 2022				34,958,730
Issuance of common stock		$ 10,732	$ 5,000		$ 4	$ 2		$ 10,728	$ 4,998
Issuance of common stock (Shares)					4,344,435	1,811,594
Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14)	6,122			$ 1			6,121
Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14) (Shares)				1,001,208
Stock options exercised	120						120
Stock options exercised (Shares)				83,235
Issuance of restricted common stock, net of tax withholdings	(445)			$ 4			(449)
Issuance of restricted common stock, net of tax withholdings, (Shares)				2,476,301
Issuance of common stock under employee stock purchase plan (ESPP)	132						132
Issuance of common stock under employee stock purchase plan (ESPP) (Shares)				79,350
Stock-based compensation	16,946						16,946
Net unrealized gains on marketable debt securities	63									$ 63
Net Income (Loss)	(73,790)										(73,790)
Ending balance at Dec. 31, 2023	125,704			$ 45			411,821			63	(286,225)
Ending balance (in shares) at Dec. 31, 2023				44,754,853
Issuance of common stock in private placement, net of offering costs (See Note 14)	39,172			$ 9			39,163
Issuance of common stock in private placement, net of offering costs (See Note 14) (Shares)				8,849,371
Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14)	12,174			$ 4			12,170
Issuance of common stock pursuant to at-the-market (ATM) program, net of offering costs (See Note 14) (Shares)				4,050,000
Issuance of pre-funded warrants in private placement, net of offering costs (See Note 15)	7,700						7,700
Stock options exercised	$ 296						296
Stock options exercised (Shares)	123,312			123,312
Issuance of restricted common stock, net of tax withholdings	$ (240)			$ 2			(242)
Issuance of restricted common stock, net of tax withholdings, (Shares)				2,088,109
Issuance of common stock under employee stock purchase plan (ESPP)	224						224
Issuance of common stock under employee stock purchase plan (ESPP) (Shares)				102,169
Stock-based compensation	12,945						12,945
Net unrealized gains on marketable debt securities	107									107
Net Income (Loss)	(77,331)										(77,331)
Ending balance at Dec. 31, 2024	$ 120,751			$ 60			$ 484,077			$ 170	$ (363,556)
Ending balance (in shares) at Dec. 31, 2024				59,967,814